Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product, LINZESS (linaclotide), treats irritable bowel syndrome with constipation and chronic idiopathic constipation in adults, as well as functional… From the company’s description.
Over the twelve months to Sep 30, 2026, Ironwood Pharmaceuticals, Inc. reported revenue of $400.30M, up 18.1% from a year earlier, and net income of $149.63M. Its operating margin was 62.9%, and operations generated $205.37M in cash. In fiscal 2025, it reported revenue of $296.15M, down 15.7% from fiscal 2024, and net income of $24.02M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ironwood Pharmaceuticals, Inc. does
In the company’s own words
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product, LINZESS (linaclotide), treats irritable bowel syndrome with constipation and chronic idiopathic constipation in adults, as well as functional constipation in children; it is marketed in some countries as CONSTELLA. Ironwood shares U.S. commercialization of LINZESS with AbbVie, while AbbVie, Astellas and AstraZeneca commercialize linaclotide in other territories. The company is advancing apraglutide, a once-weekly peptide drug candidate for short bowel syndrome with intestinal failure in patients dependent on parenteral support, and plans a confirmatory Phase III trial. Ironwood’s revenue is derived substantially from linaclotide partnerships, particularly its U.S. collaboration with AbbVie. In 2025, it recognized $289.3 million in collaborative arrangements revenue related to U.S. LINZESS sales. Its business is organized around its GI and rare-disease products and development programs, rather than reportable operating segments. Ironwood acquired VectivBio in 2023, adding apraglutide to its pipeline. Its website is www.ironwoodpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1446847
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ironwood Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ironwood Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ironwood Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ironwood Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ironwood Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”